Efficacy and safety of chondroitin sulfate/xanthan gum versus polyethylene glycol/propylene glycol/hydroxypropyl guar in patients with dry eye
Authors Llamas-Moreno JF, Baiza Durán LM, Saucedo-Rodríguez, Alaníz-De la O
Received 6 April 2013
Accepted for publication 29 April 2013
Published 29 May 2013 Volume 2013:7 Pages 995—999
Checked for plagiarism Yes
Review by Single anonymous peer review
Peer reviewer comments 3
Juan Francisco Llamas-Moreno,1 Leopoldo Martín Baiza-Durán,1 Laura Ray Saucedo-Rodríguez,2 José Félix Alaníz-De la O2
1Clinical Research Department, Laboratorios Sophia, SA de CV Zapopan, Jalisco, México; 2Ophthalmology Department, Fray Antonio Alcalde Hospital, Guadalajara, Jalisco, México
Purpose: To evaluate the efficacy and safety of two ophthalmic solutions in patients with mild to moderate dry eye.
Methods: We performed a prospective, 2-month-long, randomized, double-blind, single-center, parallel clinical trial to compare the efficacy and safety of two ophthalmic solutions for dry eye treatment. Patients were randomly assigned to one of the two treatment groups, study group or active-control group, and received one drop four times a day. The primary efficacy endpoint was to extend the tear film break-up time (TBUT) after 2 months of treatment. The Ocular Surface Disease Index (OSDI) was also evaluated. Safety measures were assessed by the presence of adverse events.
Results: A total of 28 patients with mild to moderate dry eye were included in the per protocol analysis. TBUT was similar between groups at baseline (chondroitin sulfate and xanthan gum [CS/XG] group, 5.2 ± 2.3; Systane® group, 4.7 ± 2.6; P = 0.488), after 2 months of treatment, TBUT was still similar in both groups (CS/XG group, 6.1 ± 2.5; Systane® group, 7.3 ± 2.5; P = 0.088). Baseline OSDI was similar between the groups (CS/XG group, 18.8 ± 5.3; Systane® group, 19.8 ± 7.1; P = 0.810), but after 2 months of treatment, the OSDI was significantly lower in the CS/XG group (6.7 ± 5.7 versus 10.8 ± 6.4; P = 0.049). An adverse event was present in the CS/XG group, but it was not related to the treatment.
Conclusions: In this population of patients with mild to moderate dry eye, treatment with CS/XG was as effective as treatment with Systane® with regard to TBUT; nevertheless, treatment in the CS/XG group was more effective at diminishing OSDI.
Keywords: dry eye, efficacy, safety, TBUT, OSDI
This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.Download Article [PDF] View Full Text [HTML][Machine readable]